View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Renal Cell Carcinoma
Dose ZOMETA every 3 to 4 weeks

Page

1 2 3

Real-world results confirm the benefits of dosing ZOMETA^® every 3 to 4 weeks¹⁴

Using alternative dosing schedules significantly compromises the benefits of ZOMETA¹⁴

Rate of SREs by dosing regimem^14*

*There are limitations to this study because the results are from a retrospective claims database analysis.

Treatment with ZOMETA 4 mg every 3 to 4 weeks significantly reduced the rate of skeletal morbidity (measured as number of events per month) vs no treatment¹⁴
No other dosing schedule is proven to protect patients from SREs^2,11-13

Achieve maximum potential benefit—treat with ZOMETA 4 mg every 3 to 4 weeks

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

Real-world results confirm the benefits of dosing ZOMETA® every 3 to 4 weeks14

Achieve maximum potential benefit—treat with ZOMETA 4 mg every 3 to 4 weeks

Real-world results confirm the benefits of dosing ZOMETA^® every 3 to 4 weeks¹⁴